Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 3/20 | 1.00 |
| ▸ | CDC25B | P30305 | 3/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 4/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosteviol SCHEMBL22922207 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL3489810 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL13401648 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL2987296 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL14925190 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL2025230 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL26990273 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL13401807 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| SCHEMBL17066125 | 0.87 | F10 (0.77) | F10PTPN1PTPN2CDC25BBCHE | |
| SCHEMBL13242208 | 0.87 | F10 (0.77) | F10PTPN1PTPN2CDC25BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214681-B1 | NOVEL NUTRACEUTICAL COMPOSITIONS CONTAINING STEVIOL AND USES THEREOF | DSM IP ASSETS BV (NL) | 2021-10-20 | — | — | EP | disclosed |
| EP-2595598-B1 | TOPICAL USE OF STEVIOL OR ISOSTEVIOL IN HAIR CARE | DSM IP ASSETS BV (NL) | 2017-12-06 | — | — | EP | disclosed |
| EP-2595598-B1 | TOPICAL USE OF STEVIOL OR ISOSTEVIOL IN HAIR CARE | DSM IP ASSETS BV (NL) | 2017-12-06 | — | — | EP | disclosed |
| CN-103002866-B | Flos Chrysanthemi or the derivant topical use in hair-care | DSM IP ASSETS B.V. (NL) | 2016-03-16 | — | — | CN | disclosed |
| US-20140044656-A1 | NOVEL USE | DSM IP ASSETS B.V. (NL) | 2014-02-13 | — | — | US | disclosed |
| CN-101883568-B | Nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof | DSM IP ASSETS BV | 2013-12-18 | — | — | CN | disclosed |
| EP-2595598-A2 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | DSM IP Assets B.V. (NL) | 2013-05-29 | — | — | EP | disclosed |
| US-20130115182-A1 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | DSM NUTRITIONAL PRODUCTS LTD. (NL) | 2013-05-09 | — | — | US | disclosed |
| US-20130115182-A1 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | DSM NUTRITIONAL PRODUCTS LTD. (NL) | 2013-05-09 | — | — | US | disclosed |
| US-20130115182-A1 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | DSM NUTRITIONAL PRODUCTS LTD. (NL) | 2013-05-09 | — | — | US | disclosed |
| US-20110251381-A1 | METHOD TO MAKE STEVIOL GLYCOSIDE ISOMERS | PEPSICO, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7964232-B2 | Steviol glycoside isomers | PEPSICO, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964232-B2 | Steviol glycoside isomers | PEPSICO, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110038957-A1 | NOVEL NUTRACEUTICAL COMPOSITIONS CONTAINING STEVIA EXTRACT OR STEVIA EXTRACT CONSTITUENTS AND USES THEREOF | DSM IP ASSETS B.V. (NL) | 2011-02-17 | — | — | US | disclosed |
| CN-101883568-A | Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof | DSM IP ASSETS BV | 2010-11-10 | — | — | CN | disclosed |
| EP-2214681-A1 | NOVEL NUTRACEUTICAL COMPOSITIONS CONTAINING STEVIA EXTRACT OR STEVIA EXTRACT CONSTITUENTS AND USES THEREOF | DSM IP Assets B.V. (NL) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009071277-A1 | NOVEL NUTRACEUTICAL COMPOSITIONS CONTAINING STEVIA EXTRACT OR STEVIA EXTRACT CONSTITUENTS AND USES THEREOF | DSM IP ASSETS B.V. (NL) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009038978-A2 | STEVIOL GLYCOSIDE ISOMERS | PEPSICO, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090074935-A1 | STEVIOL GLYCOSIDE ISOMERS | PEPSICO, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090074935-A1 | STEVIOL GLYCOSIDE ISOMERS | PEPSICO, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251381-A1 | METHOD TO MAKE STEVIOL GLYCOSIDE ISOMERS | DEGS1, TAS1R2, TAS2R1 | F10 1710/4885PTPN1 2056/4885PTPN2 2220/4885 |
| US-20130115182-A1 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | POLR1C, CCND3, DRD3 | F10 3541/4885PTPN1 4309/4885PTPN2 4108/4885 |
| US-20110038957-A1 | NOVEL NUTRACEUTICAL COMPOSITIONS CONTAINING STEVIA EXTRACT OR STEVIA EXTRACT CONSTITUENTS AND USES THEREOF | SYNGR2, FABP7, PSD | F10 2833/4885PTPN1 4139/4885PTPN2 3704/4885 |
| US-20140044656-A1 | NOVEL USE | TYR, TPST2, MC1R | F10 1432/4885PTPN1 3211/4885PTPN2 2029/4885 |
| US-20090074935-A1 | STEVIOL GLYCOSIDE ISOMERS | DEGS1, TAS1R2, TAS2R1 | F10 1747/4885PTPN1 2095/4885PTPN2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.